NAGE
Niagen Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.50
+0.40%Year over year
Reported trailing growth
- Revenue
- +11.0%
- EBITDA
- -4.2%
- EBIT
- -48.3%
- EPS
- -13.3%
- Free cash flow
- -72.9%
- Operating cash flow
- -72.0%
Forward estimates
Based on analyst estimates
- Revenue
- +12.1%
- EBITDA
- -38.2%
- EPS
- -52.3%
Three-year CAGR
- Revenue
- +21.6%
- EBITDA
- +90.0%
- EBIT
- +85.0%
- Net income
- +103.3%
- EPS
- +100.0%
- Free cash flow
- +37.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026